Complement Therapeutics GmbH Doses First Patient in Gene Therapy Trial for Geographic Atrophy

A new gene therapy approach is entering human trials—targeting one of the most challenging eye diseases.

Complement Therapeutics has announced that the first patient has been dosed in its Phase I/II clinical trial, Opti-GAIN, evaluating its investigational therapy CTx001.

Why This Matters?

The trial focuses on Geographic Atrophy, a severe and progressive condition linked to Age-related Macular Degeneration.

Patients with Geographic Atrophy experience:

• Gradual and irreversible vision loss
• Damage to retinal cells
• Limited treatment options

In short: high unmet medical need.

What Is CTx001?

CTx001 is not a typical drug—it’s a gene therapy.

Key Highlights

• Built on AAV2 (adeno-associated virus) technology
• Designed to deliver mini-CR1, a regulator of the complement system
• Administered via a one-time subretinal injection

Why It’s Different

CTx001 targets multiple complement pathways, which are known to drive disease progression in Geographic Atrophy.

Potential advantages include:

• Broad activity across disease mechanisms
• Localized production within the retina
• Long-lasting therapeutic effect

Inside the Opti-GAIN Trial

Opti-GAIN is a first-in-human Phase I/II study designed to assess:

• Safety
• Tolerability
• Early signs of efficacy

Study Design

• Part 1: Dose-escalation (open-label, 3 cohorts)
• Part 2: Dose expansion

The therapy is delivered as a single subretinal injection, aiming for durable benefit from one procedure.

A Smarter Clinical Strategy

What makes this program stand out is its dual-study approach.

Supporting Study: Pre-GAIN

Running alongside Opti-GAIN is Pre-GAIN, a natural history study.

Its role:

• Track disease progression
• Improve patient selection
• Help define better clinical endpoints

Together, these studies aim to de-risk development early.

Innovation in Trial Endpoints

Opti-GAIN is among the first studies to explore:

• Focal OCT-based microperimetry
• Ellipsoid zone (EZ) analysis

These advanced imaging and functional tools could:

Redefine how treatment success is measured in eye diseases.

What Experts Are Saying?

Arshad M. Khanani, the trial’s Chief Investigator, emphasized: There is a clear need for new approaches in patients facing progressive vision loss. He also highlighted the promise of a one-time gene therapy approach.

Leadership Perspective

According to Rafiq Hasan, CEO of Complement Therapeutics:

• The first patient dosing is a major milestone
• The combination of asset + clinical strategy could differentiate CTx001

Meanwhile, Muhammad Ali Memon pointed to:

• Precise surgical delivery
• Adaptive immunomodulation
• Well-characterized patient population

All designed to maximize the chances of success.

The Bigger Picture

The complement system has already been clinically validated in Geographic Atrophy.

But most current approaches:

• Target single pathways
• Require repeat dosing

CTx001 aims to change that with:

• Multi-pathway modulation
• One-time treatment
• Sustained effect

Final Takeaway

This is early-stage—but strategically important. CTx001 represents:

• A next-generation gene therapy approach
• A push toward durable, one-time treatments
• A smarter clinical model combining natural history + intervention

If successful, it could redefine how Geographic Atrophy is treated—and how future ophthalmology trials are designed.